Notice of Interim Results

RNS Number : 2412E

Epistem Holdings plc

06 February 2015

 



Notice of Interim Results

06 February 2015

Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company will be announcing its unaudited interim results for the six months ended 31 December 2014 on Thursday, 26 March 2015.

An analysts' meeting will be held at the offices of Peel Hunt LLP, Moor House, 120 London Wall, London EC2Y 5ET at 9.30 am.

For further details please contact:

Epistem Holdings Plc

Matthew Walls: Chief Executive Officer                                                         ++44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                           ++44 (0)207 418 8900

Clare Terlouw

Walbrook PR

Mike Wort                                                                                                             ++44 (0)207 933 8780

Anna Dunphy

Please see http://www.epistem.co.uk for additional information.

Notes to Editors:

About Epistem

Epistem (http://www.epistem.co.uk) is a personalised medicine and biotechnology company commercialising its technology and expertise in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and pharmacogenomics (Genedrive^®), target discovery of novel therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Pharmacogenomics), Contract Research Services and Novel Therapies.

Genedrive® (http://www.genedrive.com) provides a major advance in next-generation molecular diagnostic testing by providing a handheld, rapid, low-cost, simple-to-use 'point of care' device with high sensitivity and specificity for diagnosis of infectious diseases. Genedrive® aims to provide a 'gold standard' identification of tuberculosis and antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.

Epistem's Genedrive®platform has applications across a wide range of bacterial, viral and fungal and somatic mutation diseases for which Epistem is developing a menu of diagnostic tests.

 

END

 

 

NORDQLBBELFZBBZ